This is the most frequently reported side effect and is typical of any subcutaneous injection
Methods Reagents and chemicals [ 15 N, 13 C 5 ]valine, [ 15 N, 13 C 4 ]threonine, [ 13 C 3 ]propionate, D9 Carnitine, [2,2,2- 2 H 3 -1,2- 13 C 2 ]acetate, 20 M [2,2,3,3,3- 2 H 5 ]propionate, [2,2,3,3,4,4,4- 2 H 7 ]butyrate, [2,2,3,3,4,4,5,5,5- 2 H 9 ]pentanoate, [6,6- 2 H 2 ]glucose (D2 glucose), and [2,2,3,3,4,4,5,5,6,6- 2 H 11 ]hexanoate were from Cambridge Isotope Laboratories (Tewksbury, MA)
50-500 mcg/kg for male erectile function Non-human primates: 50 mcg/kg demonstrated erectogenic effects Human Clinical Trials: Intranasal formulation (discontinued): 7-20 mg in male ED studies
Conversely, the typical MNTI pattern is NSE(+)/MyoD1()
The Wegovy escalation model Most compounded semaglutide protocols mirror the FDA-approved Wegovy escalation schedule, even though compounded versions are not FDA-approved themselves
Borbenyi-Galambos, K., Czikora, A., Erdelyi, K
